M
Maciej Krzakowski
Researcher at Curie Institute
Publications - 119
Citations - 7084
Maciej Krzakowski is an academic researcher from Curie Institute. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 21, co-authored 89 publications receiving 6632 citations.
Papers
More filters
Journal ArticleDOI
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Robert Pirker,José Rodrigues Pereira,Aleksandra Szczesna,Joachim von Pawel,Maciej Krzakowski,Rodryg Ramlau,Ihor Vynnychenko,Keunchil Park,Chih Teng Yu,Valentyn Ganul,Jae Kyung Roh,Emilio Bajetta,Kenneth J. O'Byrne,Filippo de Marinis,Wilfried Eberhardt,Thomas Goddemeier,M. Emig,Ulrich Gatzemeier +17 more
TL;DR: Addition of cetuximab to platinum-based chemotherapy represents a new treatment option for patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu,Thomas Brodowicz,Christoph C. Zielinski,Joo Hang Kim,Maciej Krzakowski,E. Laack,Yi-Long Wu,Isabel Bover,Stephen Begbie,Valentina Tzekova,Branka Cucevic,José Rodrigues Pereira,Sung Hyun Yang,Jayaprakash Madhavan,Katherine P. Sugarman,Patrick Peterson,William J. John,K. Krejcy,Chandra P. Belani +18 more
TL;DR: Maintenance therapy with pemetrexed is well tolerated and offers improved progression-free and overall survival compared with placebo in patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck,Rolf Kaiser,Anders Mellemgaard,Jean-Yves Douillard,Sergey Orlov,Maciej Krzakowski,Joachim von Pawel,Maya Gottfried,Igor Bondarenko,Meilin Liao,Claudia-Nanette Gann,José Barrueco,Birgit Gaschler-Markefski,Silvia Novello +13 more
TL;DR: Overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group, compared with those in theDocetaxe plus placebo group.
Journal ArticleDOI
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Lee S. Rosen,David Gordon,Simon Tchekmedyian,Ronald Yanagihara,Vera Hirsh,Maciej Krzakowski,Marek Pawlicki,Paul de Souza,Ming Zheng,Gladys Urbanowitz,Dirk J. Reitsma,John J. Seaman +11 more
TL;DR: Zoledronic acid (4 mg infused over 15 minutes) is the first bisphosphonate to reduce skeletal complications in patients with bone metastases from solid tumors other than breast and prostate cancer.
Journal ArticleDOI
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
Lee S. Rosen,David Gordon,N. Simon Tchekmedyian,Ronald Yanagihara,Vera Hirsh,Maciej Krzakowski,Marek Pawlicki,Paul de Souza,Ming Zheng,Gladys Urbanowitz,Dirk J. Reitsma,John J. Seaman +11 more
TL;DR: The long‐term efficacy and safety of 21 months of treatment with zoledronic acid in a randomized, placebo‐controlled trial are reported.